hydroxyproline has been researched along with Breast Cancer in 97 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 9.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 9.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "Intravenous pamidronate is a well tolerated treatment that produced significant relief of bone pain in the majority of patients with metastatic breast cancer at the three highest doses tested." | 9.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "Breast cancer patients (n = 224) aged 28 to 81 were postoperatively followed up with serial determinations of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), and urinary hydroxyproline (OHP)." | 7.67 | A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. ( Carpi, A; Di Marco, G; Giordani, R; Giuliani, L; Nicolini, A; Palla, S, 1989) |
| "The content of hydroxyproline was determined in cancerous and noncancerous tissues obtained from 40 patients with primary breast cancer, and investigated from a clinicopathologic viewpoint." | 7.67 | [Hydroxyproline in breast cancer]. ( Iida, T, 1989) |
| "The effect of long term ascorbic acid (AA) supplementation (3g per day) on 27 women with early breast cancer has been investigated." | 7.67 | Ascorbic acid supplementation and five year survival rates in women with early breast cancer. ( Dickerson, JW; Poulter, JM; White, WF, 1984) |
| "The excretion of urinary hydroxyproline has been measured before mastectomy in 342 patients presenting with breast cancer for the first time to Guy's Hospital." | 7.67 | Urinary hydroxyproline and prognosis in human breast cancer. ( Grant, CS; Hayward, JL; Hoare, SA; Millis, RR; Wang, DY, 1984) |
| "The values of urinary hydroxyproline excretion reflecting the bone remodelling by osteoclasts, and the bone isoenzyme of serum alkaline phosphatase reflecting the osteoblastic function, in 100 randomly selected healthy subjects, 100 patients with primary hyperparathyroidism, and 100 patients with osteolytic secondary tumorous deposits in the skeleton showed a bivariate lognormal distribution." | 7.67 | Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. ( Bek, V; Broulík, P; Mikulecký, M; Pacovský, V; Stĕpán, JJ, 1989) |
| "The postabsorptive urinary hydroxyproline excretion test (Spot-HYPRO) was evaluated for its usefulness in reflecting the presence or absence of bone metastasis in 75 women with breast cancer." | 7.66 | The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer. ( McDonald, MW; Neely, CL; Niell, HB; Palmieri, GM, 1983) |
| "Postabsorptive urine hydroxyproline (HYPRO) excretion ("spot" HYPRO test) was compared with the 24-hour urine excretion of HYPRO in 45 patients with breast cancer and nine normal subjects on a low-gelatin diet." | 7.66 | Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer. ( McDonald, MW; Neely, CL; Niell, HB; Palmieri, GM, 1981) |
| "Serial estimations of the hydroxyproline (OHP) excretion during chemotherapy were performed in 24 women bearing advanced breast carcinoma with skeletal metastases." | 7.66 | [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases]. ( Fazzin, G; Maccari, F; Nascimben, O; Polico, C, 1978) |
| "In normal adult females, patients with benign breast disease and patients with breast cancer, hydroxyproline (OHPro) was found in the plasma attached to the protein fractions which were separated by Sephadex gel filtration." | 7.66 | Distribution of plasma-bound hydroxyproline in breast cancer, benign breast disease and healthy females. ( Clark, J; Cuschieri, A; Nehlawi, MF; Wood, RA, 1979) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 7.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| "The hydroxyproline/creatinine excretion ratios have been measured in half-hour fasting morning urine specimens from breast cancer patients and compared with corresponding values measured in 24 hour urine collections." | 7.65 | Early morning hydroxyproline excretion in patients with breast cancer. ( Bondy, PK; Leese, CL; Powles, TJ; Rosset, G, 1976) |
| "In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and scintigraphic parameters." | 7.65 | Relevance of hydroxyproline excretion to bone metastasis in breast cancer. ( Dequeker, J; Drochmans, A; Gielen, F; Merlevede, M; Wildiers, J, 1976) |
| "15 patients with breast cancer and proven bone metastases have been studied." | 5.26 | [Hydroxyproline in the diagnosis of bone metastases in breast cancer]. ( Alberto, P; Courvoisier, B; Depierre, D; Gasser, AB, 1977) |
| "When surgery fails to cure breast cancer it is due to disseminated micrometastases present at the time of operation." | 5.26 | Hydroxyproline excretion in the detection of occult bone metastases from breast cancer. ( Banks, AJ; Morrison, MJ; Roginski, C; Rowse, AD; Scott, PH, 1982) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 5.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 5.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Intravenous pamidronate is a well tolerated treatment that produced significant relief of bone pain in the majority of patients with metastatic breast cancer at the three highest doses tested." | 5.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| " Eight of these patients had either hypercalcemia or hypercalciuria, and all 10 had elevated urinary hydroxyproline levels as evidence of active skeletal disease." | 5.05 | Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. ( Canfield, RE; Hyman, GA; Siris, ES, 1983) |
| " We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate." | 3.69 | Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. ( Body, JJ; Delmas, PD; Dumon, JC; Gineyts, E, 1997) |
| "The effect of long term ascorbic acid (AA) supplementation (3g per day) on 27 women with early breast cancer has been investigated." | 3.67 | Ascorbic acid supplementation and five year survival rates in women with early breast cancer. ( Dickerson, JW; Poulter, JM; White, WF, 1984) |
| "The excretion of urinary hydroxyproline has been measured before mastectomy in 342 patients presenting with breast cancer for the first time to Guy's Hospital." | 3.67 | Urinary hydroxyproline and prognosis in human breast cancer. ( Grant, CS; Hayward, JL; Hoare, SA; Millis, RR; Wang, DY, 1984) |
| "The content of hydroxyproline was determined in cancerous and noncancerous tissues obtained from 40 patients with primary breast cancer, and investigated from a clinicopathologic viewpoint." | 3.67 | [Hydroxyproline in breast cancer]. ( Iida, T, 1989) |
| "Breast cancer patients (n = 224) aged 28 to 81 were postoperatively followed up with serial determinations of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), and urinary hydroxyproline (OHP)." | 3.67 | A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. ( Carpi, A; Di Marco, G; Giordani, R; Giuliani, L; Nicolini, A; Palla, S, 1989) |
| "The values of urinary hydroxyproline excretion reflecting the bone remodelling by osteoclasts, and the bone isoenzyme of serum alkaline phosphatase reflecting the osteoblastic function, in 100 randomly selected healthy subjects, 100 patients with primary hyperparathyroidism, and 100 patients with osteolytic secondary tumorous deposits in the skeleton showed a bivariate lognormal distribution." | 3.67 | Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. ( Bek, V; Broulík, P; Mikulecký, M; Pacovský, V; Stĕpán, JJ, 1989) |
| "Serial estimations of the hydroxyproline (OHP) excretion during chemotherapy were performed in 24 women bearing advanced breast carcinoma with skeletal metastases." | 3.66 | [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases]. ( Fazzin, G; Maccari, F; Nascimben, O; Polico, C, 1978) |
| "The postabsorptive urinary hydroxyproline excretion test (Spot-HYPRO) was evaluated for its usefulness in reflecting the presence or absence of bone metastasis in 75 women with breast cancer." | 3.66 | The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer. ( McDonald, MW; Neely, CL; Niell, HB; Palmieri, GM, 1983) |
| "Seventy-one patients with breast cancer and bone metastases, together with other assessable sites of disease, were monitored by radiologic skeletal survey, bone scanning, pain charts, bone marrow aspirate, serum calcium, alkaline phosphatase and urine hydroxyproline/creatinine ratio." | 3.66 | Assessment of response of bone metastases to systemic treatment in patients with breast cancer. ( Coombes, RC; Dady, P; Ford, HT; Gazet, JC; McCready, VR; Parsons, C; Powles, TJ, 1983) |
| "The authors study the daily elimination of hydroxyproline in breast cancer with and without roentgenological or radioisotopic bone scanning evidence of bone lesion." | 3.66 | [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer]. ( Espinós Pérez, D; Millán Núñez-Cortés, J; Rico Lenza, H; Rodríguez Mora, VI, 1980) |
| "Postabsorptive urine hydroxyproline (HYPRO) excretion ("spot" HYPRO test) was compared with the 24-hour urine excretion of HYPRO in 45 patients with breast cancer and nine normal subjects on a low-gelatin diet." | 3.66 | Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer. ( McDonald, MW; Neely, CL; Niell, HB; Palmieri, GM, 1981) |
| "The Authors have studied total urinary hydroxyproline (TUH), together with other hematochemical analyses, in 104 patients suffering from advanced breast cancer with or without bone metastases." | 3.66 | [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]. ( Biagi, R; Colalongo, G; Jafelice, G; Mambelli, M; Martoni, A; Pannuti, F; Pedelini, G; Piana, E; Rocchetta, G, 1980) |
| "The urinary excretion of Hydroxyproline (OH-P), evaluated as OH-P/creatinine ratio, has been examined in the follow up of 142 breast cancer patients." | 3.66 | [Hydroxyprolinuria and bone metastases of breast cancer]. ( Bardella, D; Cruciani, G; Fiorentini, GM; Marangolo, M; Tavolazzi, L, 1980) |
| "In normal adult females, patients with benign breast disease and patients with breast cancer, hydroxyproline (OHPro) was found in the plasma attached to the protein fractions which were separated by Sephadex gel filtration." | 3.66 | Distribution of plasma-bound hydroxyproline in breast cancer, benign breast disease and healthy females. ( Clark, J; Cuschieri, A; Nehlawi, MF; Wood, RA, 1979) |
| " Examples of this latter category include the changes in urinary hydroxyproline output in patients with bone metastases or the altered levels of serum acute phase proteins in neoplasia in general." | 3.66 | The monitoring role of plasma CEA alone and in association with other tumor markers in colorectal and mammary carcinoma. ( Capp, M; Coombes, RC; Cooper, EH; Laurence, DJ; Neville, AM; Patel, S; Turberville, C, 1978) |
| "In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and scintigraphic parameters." | 3.65 | Relevance of hydroxyproline excretion to bone metastasis in breast cancer. ( Dequeker, J; Drochmans, A; Gielen, F; Merlevede, M; Wildiers, J, 1976) |
| " Seven of these parameters were raised in more than half of the 17 patients of the series with overt metastases; these were serum ferritin (88%), C-reactive protein (87%), carcinoembryonic antigen (81%), acid glycoprotein (75%), total alkaline phosphatase (64%), sialyl transferase (56%), andthe urinary hydroxyproline/creatinine ratio (73%)." | 3.65 | Biochemical markers in human breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Laurence, DJ; Neville, AM; Powles, TJ; Sloane, JP, 1977) |
| "The hydroxyproline/creatinine excretion ratios have been measured in half-hour fasting morning urine specimens from breast cancer patients and compared with corresponding values measured in 24 hour urine collections." | 3.65 | Early morning hydroxyproline excretion in patients with breast cancer. ( Bondy, PK; Leese, CL; Powles, TJ; Rosset, G, 1976) |
| " We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer." | 3.65 | Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. ( Bondy, PK; Coombes, RC; Neville, AM; Powles, TJ, 1976) |
| "In this malignancy, the HCG level suggests the diagnosis and stage, confirms response to therapy, and predicts relapse." | 2.37 | Tumor markers: value and limitations in the management of cancer patients. ( Bates, SE; Longo, DL, 1985) |
| "In a quantitative proteomics-based breast cancer study of complementary normal and tumor biopsies, 22 collagen isoforms were detected by LC-MALDI TOF/TOF MS." | 1.38 | Proteomic profiling of breast tissue collagens and site-specific characterization of hydroxyproline residues of collagen alpha-1-(I). ( Hadjisavvas, A; Kyriacou, K; Montgomery, H; Rustogi, N; Sutton, CW; Tanaka, K, 2012) |
| "Hydroxyproline was also measured." | 1.29 | Biochemical markers for detecting bone metastases in patients with breast cancer. ( Crivellari, D; de Bernard, B; Galligioni, E; Gazzarrini, C; Moro, L; Talamini, R, 1993) |
| "Malignant hypercalcemia is caused by both increased bone resorption and enhanced tubular reabsorption of calcium." | 1.28 | Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. ( Burckhardt, P; Jaeger, P; Thiebaud, D, 1990) |
| "Biochemical evaluation showed that bone resorption from metastatic disease was generally not enough to account for hypercalcaemia." | 1.27 | Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. ( Boyle, IT; Fogelman, I; Gardiner, MD; Ralston, SH, 1984) |
| "Increases without any evidence of metastases are either due to other diseases with connective tissue changes or to occult micrometastases." | 1.27 | [The value of the free hydroxyproline and the N-acetyl-beta- glucosaminidase for the observation of the course of malignant tumors]. ( Lange, H; Müller, A; Ruffert, K, 1986) |
| "In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios." | 1.27 | Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer. ( Hopkins, SC; Maxwell, TA; Neely, CL; Niell, HB; Palmieri, GM; Soloway, MS, 1983) |
| "The desmoplastic response to breast carcinoma is being studied." | 1.27 | Collagen and elastin synthesis in human stroma and breast carcinoma cell lines: modulation by the extracellular matrix. ( Hall, J; Kao, RT; Stern, R, 1986) |
| "Patients with breast cancer may show an increased requirement for thiamin particularly when treated with 5-fluorouracil, and a number of metabolic disturbances in which ascorbic acid may play a central role." | 1.26 | Nutrition and breast cancer. ( Dickerson, JW, 1979) |
| "When surgery fails to cure breast cancer it is due to disseminated micrometastases present at the time of operation." | 1.26 | Hydroxyproline excretion in the detection of occult bone metastases from breast cancer. ( Banks, AJ; Morrison, MJ; Roginski, C; Rowse, AD; Scott, PH, 1982) |
| "15 patients with breast cancer and proven bone metastases have been studied." | 1.26 | [Hydroxyproline in the diagnosis of bone metastases in breast cancer]. ( Alberto, P; Courvoisier, B; Depierre, D; Gasser, AB, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 87 (89.69) | 18.7374 |
| 1990's | 9 (9.28) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montgomery, H | 1 |
| Rustogi, N | 1 |
| Hadjisavvas, A | 1 |
| Tanaka, K | 1 |
| Kyriacou, K | 1 |
| Sutton, CW | 1 |
| RUBEGNI, M | 1 |
| RAVENNI, G | 1 |
| DEL GIOVANE, L | 1 |
| KLEIN, L | 1 |
| LAFFERTY, FW | 1 |
| PEARSON, OH | 1 |
| CURTISS, PH | 1 |
| Platt, WD | 1 |
| Doolittle, LH | 1 |
| Hartshorn, JW | 1 |
| LEE, CA | 2 |
| LLOYD, HM | 2 |
| Waalkes, TP | 3 |
| Abeloff, MD | 1 |
| Ettinger, DS | 1 |
| Woo, KB | 1 |
| Gehrke, CW | 2 |
| Mrochek, JE | 1 |
| Coombes, RC | 8 |
| Powles, TJ | 9 |
| Ford, HT | 6 |
| Gazet, JC | 6 |
| Keyser, JW | 2 |
| Mitchell, PE | 1 |
| Patel, S | 2 |
| Stimson, WH | 2 |
| Abbott, M | 1 |
| Worwood, M | 1 |
| Neville, AM | 6 |
| Schulze, G | 1 |
| Siris, ES | 2 |
| Hyman, GA | 1 |
| Canfield, RE | 2 |
| Dearnaley, DP | 1 |
| Buckman, R | 1 |
| Jones, JM | 1 |
| Ormerod, MG | 1 |
| Sloane, JP | 3 |
| Ralston, SH | 1 |
| Fogelman, I | 1 |
| Gardiner, MD | 1 |
| Boyle, IT | 1 |
| Dady, PJ | 1 |
| Smith, IE | 1 |
| Parsons, CA | 1 |
| Henk, JM | 2 |
| Nash, AG | 2 |
| Poulter, JM | 1 |
| White, WF | 1 |
| Dickerson, JW | 4 |
| Niell, HB | 3 |
| Neely, CL | 3 |
| Palmieri, GM | 3 |
| McDonald, MW | 2 |
| Maxwell, TA | 1 |
| Hopkins, SC | 1 |
| Soloway, MS | 1 |
| Bellido, V | 1 |
| Carda, P | 1 |
| Mascías, E | 1 |
| Grant, CS | 1 |
| Hoare, SA | 1 |
| Millis, RR | 1 |
| Hayward, JL | 1 |
| Wang, DY | 1 |
| Statland, BE | 1 |
| Winkel, P | 1 |
| Kelleher, PC | 1 |
| Smith, CJ | 1 |
| Dady, P | 1 |
| Parsons, C | 1 |
| McCready, VR | 1 |
| Lewko, WM | 1 |
| Liotta, LA | 1 |
| Wicha, MS | 1 |
| Vonderhaar, BK | 1 |
| Kidwell, WR | 1 |
| Tormey, DC | 2 |
| Gasser, AB | 2 |
| Depierre, D | 2 |
| Mermillod, B | 1 |
| Courvoisier, B | 2 |
| Rowse, AD | 1 |
| Morrison, MJ | 1 |
| Scott, PH | 1 |
| Banks, AJ | 1 |
| Roginski, C | 1 |
| Rico Lenza, H | 1 |
| Millán Núñez-Cortés, J | 1 |
| Rodríguez Mora, VI | 1 |
| Espinós Pérez, D | 1 |
| Posma, FD | 1 |
| Groenewold, H | 1 |
| Kluft, O | 1 |
| Tuynman, FH | 1 |
| Hogan-Ryan, A | 1 |
| Fennelly, JJ | 1 |
| Jones, M | 1 |
| Cantwell, B | 1 |
| Duffy, MJ | 1 |
| Martoni, A | 1 |
| Pedelini, G | 1 |
| Colalongo, G | 1 |
| Biagi, R | 1 |
| Mambelli, M | 1 |
| Jafelice, G | 1 |
| Rocchetta, G | 1 |
| Piana, E | 1 |
| Pannuti, F | 1 |
| Cruciani, G | 1 |
| Bardella, D | 1 |
| Fiorentini, GM | 1 |
| Marangolo, M | 1 |
| Tavolazzi, L | 1 |
| Glover, D | 1 |
| Lipton, A | 2 |
| Keller, A | 1 |
| Miller, AA | 1 |
| Browning, S | 1 |
| Fram, RJ | 1 |
| George, S | 1 |
| Zelenakas, K | 1 |
| Macerata, RS | 1 |
| Seaman, JJ | 2 |
| Ward, RL | 1 |
| Morgan, G | 1 |
| Dalley, D | 1 |
| Kelly, PJ | 1 |
| Taube, T | 1 |
| Elomaa, I | 1 |
| Blomqvist, C | 1 |
| Beneton, MN | 1 |
| Kanis, JA | 2 |
| Moro, L | 1 |
| Gazzarrini, C | 1 |
| Crivellari, D | 1 |
| Galligioni, E | 1 |
| Talamini, R | 1 |
| de Bernard, B | 1 |
| Body, JJ | 3 |
| Dumon, JC | 2 |
| Piccart, M | 1 |
| Ford, J | 1 |
| Gineyts, E | 1 |
| Delmas, PD | 1 |
| Hortobagyi, GN | 1 |
| Theriault, RL | 1 |
| Porter, L | 1 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Knight, RD | 1 |
| Heffernan, M | 1 |
| Mellars, K | 1 |
| Reitsma, DJ | 1 |
| Laurence, DJ | 2 |
| Mach, JP | 1 |
| Fritsche, R | 1 |
| Phan, M | 1 |
| Ozzello, L | 1 |
| Stjernsward, J | 1 |
| van Breukelen, FJ | 1 |
| Bijvoet, OL | 2 |
| van Oosterom, AT | 1 |
| Nehlawi, MF | 1 |
| Cuschieri, A | 7 |
| Clark, J | 1 |
| Wood, RA | 1 |
| Basu, TK | 4 |
| Jarvie, R | 1 |
| Taylor, WH | 1 |
| Cant, E | 1 |
| Furnival, CM | 1 |
| Blumgart, LH | 1 |
| Capp, M | 1 |
| Cooper, EH | 1 |
| Turberville, C | 1 |
| Polico, C | 1 |
| Nascimben, O | 1 |
| Maccari, F | 1 |
| Fazzin, G | 1 |
| Hillyard, CJ | 1 |
| Thomas, P | 1 |
| Marcus, D | 1 |
| Zinberg, N | 1 |
| Alberto, P | 1 |
| Gielen, F | 1 |
| Dequeker, J | 1 |
| Drochmans, A | 1 |
| Wildiers, J | 1 |
| Merlevede, M | 1 |
| Rosset, G | 1 |
| Leese, CL | 2 |
| Bondy, PK | 3 |
| Roberts, JG | 2 |
| Baum, M | 3 |
| Williams, M | 1 |
| Bligh, AS | 1 |
| Lester, E | 1 |
| Rotstein, S | 1 |
| Glas, U | 1 |
| Eriksson, M | 1 |
| Pfeiffer, P | 1 |
| Hansen, J | 1 |
| Söderqvist, J | 1 |
| Bandmann, U | 1 |
| Strid, S | 1 |
| Thiebaud, D | 1 |
| Jaeger, P | 1 |
| Burckhardt, P | 1 |
| Bates, SE | 1 |
| Longo, DL | 1 |
| Ruffert, K | 1 |
| Müller, A | 1 |
| Lange, H | 1 |
| Iida, T | 1 |
| Nicolini, A | 1 |
| Carpi, A | 1 |
| Di Marco, G | 1 |
| Giuliani, L | 1 |
| Giordani, R | 1 |
| Palla, S | 1 |
| Stĕpán, JJ | 1 |
| Mikulecký, M | 1 |
| Bek, V | 2 |
| Broulík, P | 1 |
| Pacovský, V | 1 |
| Kao, RT | 1 |
| Hall, J | 1 |
| Stern, R | 2 |
| Jacobs, TP | 1 |
| Borkowski, A | 1 |
| Cleeren, A | 1 |
| Marotta, M | 1 |
| Martino, G | 1 |
| D'Armiento, FP | 1 |
| Aiello, AM | 1 |
| Roberti, ML | 1 |
| Vecchione, R | 1 |
| Rosati, P | 1 |
| Oda, D | 1 |
| Gown, AM | 1 |
| Vande Berg, JS | 1 |
| Frenay, M | 1 |
| Namer, M | 1 |
| Boublil, JL | 1 |
| Khater, R | 1 |
| Viot, M | 1 |
| François, E | 1 |
| Milano, G | 1 |
| Hausner, P | 1 |
| Stĕpán, J | 1 |
| Kolár, J | 1 |
| Vosecký, M | 1 |
| Konopásek, B | 1 |
| Nový, F | 1 |
| Janko, L | 1 |
| Coleman, RE | 1 |
| Rubens, RD | 1 |
| Solov'ev, IE | 1 |
| Iurzhenko, NN | 1 |
| Stevens, MJ | 1 |
| Percival, RC | 1 |
| Yates, AJ | 1 |
| Gray, RE | 1 |
| Galloway, J | 1 |
| Rogers, K | 1 |
| Neal, FE | 1 |
| Radom, S | 2 |
| Zulawski, M | 2 |
| Golebiowska, D | 1 |
| Raven, RW | 2 |
| Williams, DC | 3 |
| Parsons, V | 2 |
| Dalley, V | 1 |
| Brinkley, D | 1 |
| Davies, C | 1 |
| Vernon, A | 1 |
| Donaldson, D | 1 |
| Dahlig, E | 1 |
| Sumner, DS | 1 |
| Edwards, MH | 1 |
| Felgate, RA | 1 |
| Felgate, R | 1 |
| Cochran, M | 1 |
| Peacock, M | 1 |
| Sachs, G | 1 |
| Nordin, BE | 1 |
| Katz, FH | 1 |
| Kappas, A | 1 |
| Mirejovská, E | 1 |
| Beska, F | 1 |
| Pitronová, M | 1 |
| Kerkhoff, JF | 1 |
| Ditzel, J | 2 |
| Jordal, R | 2 |
| Riskoer, N | 1 |
| Riskaer, N | 1 |
| Guzzo, CE | 1 |
| Pachas, WN | 1 |
| Pinals, RS | 1 |
| Krant, MJ | 1 |
| Hosley, HF | 1 |
| Taft, EG | 1 |
| Olson, KB | 1 |
| Gates, S | 1 |
| Beebe, RT | 1 |
| Mühlbach, R | 2 |
| Hirthe, D | 1 |
| Lindenhayn, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for hydroxyproline and Breast Cancer
| Article | Year |
|---|---|
Usefulness of clinical chemistry measurements in classifying patients with breast cancer.
Topics: Alkaline Phosphatase; Apolipoproteins; Apolipoproteins D; beta 2-Microglobulin; Breast Neoplasms; Ca | 1982 |
Collagen metabolites in the urine and serum of patients with cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Collagen; Colorimetry; Female; Humans; Hydroxylysine; Hydroxyproli | 1982 |
Biological markers as prognostic and clinical evaluation tools.
Topics: Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Chorionic Gonadotropin; Creatinine; Fema | 1980 |
Search for biological markers in breast cancer.
Topics: Alpha-Globulins; alpha-Macroglobulins; Antibodies, Viral; Antigens; Breast Neoplasms; Calcitonin; Ca | 1977 |
Biologic markers and breast cancer.
Topics: alpha-Macroglobulins; Blood Proteins; Breast Neoplasms; Calcitonin; Carbohydrates; Carcinoembryonic | 1978 |
Tumor markers: value and limitations in the management of cancer patients.
Topics: Acid Phosphatase; Adrenocorticotropic Hormone; Alkaline Phosphatase; alpha-Fetoproteins; Breast Neop | 1985 |
10 trials available for hydroxyproline and Breast Cancer
| Article | Year |
|---|---|
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clini | 1983 |
Free serum hydroxyproline and total urinary hydroxyproline for the detection of skeletal metastasis.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trial | 1982 |
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Bone Neoplasms; Bre | 1994 |
Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Oral; Bone Density; Breast Neoplasms; Female; Femur Neck; Hu | 1993 |
Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; | 1993 |
Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Topics: Adult; Aged; Analysis of Variance; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitriol; Ca | 1995 |
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Alkaline Phosphatase; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1998 |
Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Bone Neoplasms; Breast Neoplasms; Calcium; Clodronic | 1992 |
Dichloromethylene diphosphonate action in hematologic and other malignancies.
Topics: Administration, Oral; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Tr | 1987 |
Circadian rhythm of total urinary hydroxyproline excretion and 3-H hydroxyproline test.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Circadian Rhythm; Clinical Trials as Topic; Female; H | 1972 |
81 other studies available for hydroxyproline and Breast Cancer
| Article | Year |
|---|---|
Proteomic profiling of breast tissue collagens and site-specific characterization of hydroxyproline residues of collagen alpha-1-(I).
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Biopsy; Breast Neoplasms; Case-Control Studies; | 2012 |
[Increase of urinary elimination of hydroxyproline in osteolytic processes].
Topics: Bone Neoplasms; Breast Neoplasms; Humans; Hydroxyproline; Male; Neoplasm Metastasis; Prostatic Neopl | 1962 |
CORRELATION OF URINARY HYDROXYPROLINE, SERUM ALKALINE PHOSPHATASE AND SKELETAL CALCIUM TURNOVER.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Calcium; Geri | 1964 |
URINARY HYDROXYPROLINE EXCRETION IN METASTATIC CANCER OF BONE.
Topics: Acid Phosphatase; Biomedical Research; Bone Neoplasms; Breast Neoplasms; Collagen; Humans; Hydroxypr | 1964 |
URINARY HYDROXYPROLINE IN DISEASES INVOLVING BONE AND CALCIUM METABOLISM.
Topics: Acute Kidney Injury; Alkaline Phosphatase; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Calcium; | 1964 |
Multiple biological markers and breast carcinoma: a preliminary study in the detection of recurrent disease after primary therapy.
Topics: Aminoisobutyric Acids; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Creatinine; Femal | 1981 |
The value of sequential marker estimations following mastectomy for breast cancer.
Topics: Alkaline Phosphatase; Breast Neoplasms; Carcinoembryonic Antigen; gamma-Glutamyltransferase; Humans; | 1980 |
[Clinical value of enzyme parameter combinations in the diagnosis of metastases].
Topics: Acid Phosphatase; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Female; gamma-Glutamyltran | 1983 |
Detection of bone metastases in patients with breast cancer.
Topics: Biopsy, Needle; Bone and Bones; Bone Marrow Examination; Bone Neoplasms; Breast Neoplasms; Diphospho | 1982 |
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
Topics: Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Carcinoma, Bronchogenic; | 1984 |
Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Doxorubicin; Drug Therapy, Combination; Fema | 1980 |
Ascorbic acid supplementation and five year survival rates in women with early breast cancer.
Topics: Adult; Aged; Ascorbic Acid; Breast Diseases; Breast Neoplasms; Creatinine; Female; Humans; Hydroxypr | 1984 |
The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Middle Aged; Radiogra | 1983 |
Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Collagen; Dialysis; Female; Hodgkin Disease; Humans; Hydroxyprolin | 1983 |
[Urinary hydroxyproline and cancer of the breast].
Topics: Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Humans; Hydroxyproline | 1983 |
Urinary hydroxyproline and prognosis in human breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Humans; Hydroxyproline; Middle Ag | 1984 |
Assessment of response of bone metastases to systemic treatment in patients with breast cancer.
Topics: Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Breast | 1983 |
Sensitivity of N-nitrosomethylurea-induced rat mammary tumors to cis-hydroxyproline, an inhibitor of collagen production.
Topics: Animals; Autoradiography; Basement Membrane; Breast Neoplasms; Cell Line; Collagen; Female; Fluoresc | 1981 |
Hydroxyproline excretion in the detection of occult bone metastases from breast cancer.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Creatinine; Evaluation Studies as Topic; Female; H | 1982 |
[Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Middle Aged | 1980 |
Reference values and analytical performance of the hydroxyproline/creatinine ratio in early morning urine samples.
Topics: Adult; Aged; Breast Neoplasms; Creatinine; Fasting; Female; Humans; Hydroxyproline; Male; Middle Age | 1981 |
Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Gelatin; Humans; Hydroxyproline | 1981 |
Serum sialic acid and CEA concentrations in human breast cancer.
Topics: Alkaline Phosphatase; Blood Sedimentation; Breast Neoplasms; Carcinoembryonic Antigen; Female; Human | 1980 |
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Medroxyprogesterone; | 1980 |
[Hydroxyprolinuria and bone metastases of breast cancer].
Topics: Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Follow-Up Studies; Humans; Hydroxyproline | 1980 |
Biochemical markers for detecting bone metastases in patients with breast cancer.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neo | 1993 |
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Biomarkers; Bone Neoplasms; Bone Resorption; Breast | 1997 |
Biochemical markers in human breast cancer.
Topics: Adenofibroma; Alkaline Phosphatase; Breast Neoplasms; C-Reactive Protein; Carcinoembryonic Antigen; | 1977 |
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Topics: Bone Resorption; Breast Neoplasms; Calcium; Creatinine; Diphosphonates; Female; Humans; Hydroxyproli | 1979 |
Nutrition and breast cancer.
Topics: Animals; Ascorbic Acid; Bone Neoplasms; Breast Neoplasms; Calcium; Dietary Fats; Feeding Behavior; F | 1979 |
Distribution of plasma-bound hydroxyproline in breast cancer, benign breast disease and healthy females.
Topics: Breast Diseases; Breast Neoplasms; Chromatography, Gel; Female; Humans; Hydroxyproline | 1979 |
Specific vitamin deficiencies and their significance in patients with cancer and receiving chemotherapy.
Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Breast Neoplasms; Female; Humans; Hydroxyproline; Lipid Met | 1977 |
Three-centre study on urinary hydroxyproline excretion in cancer of the breast.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Methods; Middle Aged; | 1978 |
The monitoring role of plasma CEA alone and in association with other tumor markers in colorectal and mammary carcinoma.
Topics: Breast Neoplasms; C-Reactive Protein; Carcinoembryonic Antigen; Colonic Neoplasms; Enzymes; Female; | 1978 |
[Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline | 1978 |
Urinary hydroxyproline in the management of breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Castration; Diethylstilbestrol; Female; Humans; Hydroxyproline; Ne | 1977 |
A biochemical approach to the staging of human breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; C-Reactive Protein; Calcitonin; | 1977 |
[Hydroxyproline in the diagnosis of bone metastases in breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Creatinine; False Negative Reactions; Female; Humans; | 1977 |
Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Female; Hu | 1976 |
Early morning hydroxyproline excretion in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Creatine; Female; Humans; Hydroxyproline; Neoplasm Metastasis; Tim | 1976 |
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.
Topics: Aspirin; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hype | 1976 |
Hydroxyproline excretion in patients with breast cancer and response to treatment.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Ethinyl Estradiol; Female; Humans; | 1975 |
Letter: Predictive value of hydroxyproline: creatinine ratio in advanced breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Humans; Hydroxyproline; Neoplasm Metastasis; R | 1975 |
Urinary hydroxyproline excretion and survival in cancer of the breast.
Topics: Breast Neoplasms; Female; Humans; Hydroxyproline | 1975 |
The hypronosticon test in breast cancer.
Topics: Adult; Aged; Body Surface Area; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Creatinine; Female | 1975 |
Proceedings: Urinary hydorxyproline excretion in the monitoring of carcinoma of the breast.
Topics: Breast Neoplasms; Female; Humans; Hydroxyproline; Neoplasm Metastasis | 1976 |
Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Topics: Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Diphosphonates; Female; Humans; | 1990 |
[The value of the free hydroxyproline and the N-acetyl-beta- glucosaminidase for the observation of the course of malignant tumors].
Topics: Acetylglucosaminidase; Bone Neoplasms; Breast Neoplasms; Female; Hexosaminidases; Hodgkin Disease; H | 1986 |
[Hydroxyproline in breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Age Factors; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Co | 1989 |
A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Follow-U | 1989 |
Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
Topics: Adult; Alkaline Phosphatase; Biomarkers; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Breast N | 1989 |
Collagen and elastin synthesis in human stroma and breast carcinoma cell lines: modulation by the extracellular matrix.
Topics: Breast Neoplasms; Cell Line; Chromatography, High Pressure Liquid; Collagen; Elastin; Estradiol; Ext | 1986 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
Collagen in human breast cancer: morphological and biochemical study.
Topics: Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Collagen; Electrophoresis, Polyac | 1985 |
The fibroblast-like nature of myofibroblasts.
Topics: Actins; Breast Neoplasms; Carcinoma; Chromatography, DEAE-Cellulose; Chromatography, High Pressure L | 1988 |
Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients.
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies | 1988 |
[Comprehensive diagnostic approaches to tumor metastases in the skeleton. V. The relation of biochemical indicators to age in the diagnosis of bone metastases of stage II carcinoma of the breast. Analysis of additional diagnostic and prognostic parameters
Topics: Age Factors; Alkaline Phosphatase; Analysis of Variance; Bone Neoplasms; Breast Neoplasms; Carcinoma | 1987 |
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hydroxyprolin | 1987 |
[Urinary polyamines and hydroxyproline in patients with breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Hydroxyproline; Middle Aged; Neoplasm Staging; Putres | 1986 |
Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
Topics: Adenosine Diphosphate; Bone Neoplasms; Breast Neoplasms; Calcium; Drug Evaluation; Female; Humans; H | 1987 |
Mechanism of malignant hypercalcaemia in carcinoma of the breast.
Topics: Absorption; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Female; Humans; Hydroxyproline; H | 1985 |
Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma, Intraductal, Noninfiltra | 1972 |
Proceedings: Urinary hydroxyproline and leucocyte ascorbic acid levels in patients bearing breast tumour with skeletal metastases.
Topics: Age Determination by Skeleton; Ascorbic Acid; Breast Neoplasms; Collagen; Female; Humans; Hydroxypro | 1974 |
The effects of calcitonin on the metabolic disturbances surrounding widespread bony metastases.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Bronchial Neoplasms; Calcitonin | 1974 |
Urinary hydroxyproline and plasma mucoprotein as an indication of the presence of bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Female; Humans; Hydroxyprolin | 1974 |
Leucocyte ascorbic acid and urinary hydroxyproline levels in patients bearing breast cancer with skeletal metastases.
Topics: Ascorbic Acid; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Leukocytes; Male; N | 1974 |
'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.
Topics: Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Methods; Neoplasm Metastasis; Radi | 1973 |
Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; | 1973 |
Urinary hydroxyproline excretion in carcinoma of the breast.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Creatinine; Female; Humans; Hydroxyproline; Middle Aged; Ne | 1972 |
Bone collagen and calcium metabolism in normocalcemic and hypercalcemic patients with breast cancer.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Co | 1971 |
Urinary hydroxyproline excretion in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Hydroxyproline; Neoplasm Metastasis | 1971 |
Renal effects of calcitonin.
Topics: Aged; Animals; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Female; Humans; Hydroxyprolin | 1970 |
Influence of estradiol and estriol on urinary excretion of hydroxyproline in man.
Topics: Acromegaly; Adult; Aged; Breast Neoplasms; Creatinine; Estradiol; Estriol; Estrogens; Female; Growth | 1968 |
The significance of hydroxyprolinuia for the proof of bone metastases of tumours.
Topics: Bone Neoplasms; Breast Neoplasms; Humans; Hydroxyproline; Lung Neoplasms; Neoplasm Metastasis; Radio | 1968 |
A rapid serum screening test for increased osteoblastic activity.
Topics: Adolescent; Adult; Alkaline Phosphatase; Blood Chemical Analysis; Bone and Bones; Bone Development; | 1968 |
[Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hydroxyproline; Hypophysectomy; Middl | 1968 |
Total urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast carcinoma.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Chemistry, | 1968 |
Urinary hydroxyproline excretion in patients with cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Creatine; Female; Humans; | 1969 |
Hydroxyproline excretion in malignant neoplastic disease.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Carcinoma, Bronchogenic; Female | 1966 |
[Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
Topics: Adult; Animals; Bone Neoplasms; Breast Neoplasms; Child; Female; Humans; Hydroxyproline; Metabolic D | 1966 |
[On the excretion of bound hydroxyproline as an expression of changes in the organic cartilage and bone matrix].
Topics: Adolescent; Bone and Bones; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cartilage; Ehlers-Danlo | 1966 |